论文部分内容阅读
Our study aimed at the investigation of in vivo anticancer effect of the combination use of dexamethasone (DEX) and gemcitabine (GM) as well as the development of pharmacokinetic/pharmacodynamic (PK/PD) models in MCF-7/Adrxenograft model.Further, simulations were conducted to optimize doses and administration schedules.The inhibitory effect of different doses and administration schedules were investigated in MCF-7/Adrxenograft model.Semi-mechanism-based PK/PD models were established based on the preclinical data to characterize the relationship between plasma concentration and the time-course of the drug response quantitatively.